First-line diagnosis based on immunological phenotyping in suspected acute leukemia: A prospective study

Kristensen, Jörgen; Ellegaard, Jørgen; Hansen, Knud Bendix; Clausen, Niels; Hokland, Peter

doi:10.1016/0145-2126(88)90011-2

Cited by 17 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Classification of individual cases according to the FAB system was based upon examination of cell morphology and enzymatic reactivity, and thus not upon reactivity with antibodies. Our flow cytometry (FCM)‐based approach to immunophenotyping in human leukaemia, which was employed throughout the years 1985–1999, has been described on several occasions (11, 20, 22–24). Throughout, this immunophenotyping included evaluation of leukaemia cell reactivity with antibodies against leukocyte differentiation antigens CD3, CD10, CD13, CD14, CD19, CD33, and MHC class II (HLA‐DR).…”

Section: Methodsmentioning

confidence: 99%

FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara‐C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia

Nørgaard¹,

Olesen²,

Olesen³

et al. 2001

European J of Haematology

Self Cite

View full text Add to dashboard Cite

In 145 adult patients diagnosed with non-M3 acute myeloid leukaemia (AML) the relevance of FAB-subtype and immunophenotype to in vitro cellular drug resistance towards the anthracyclines aclarubicin (Acla) and daunorubicin (Dau), and the nucleoside analogue cytarabine (Ara-C), as well as other antileukaemic drugs, was investigated using a 4-d MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay. We demonstrate that high CD14 expression is highly significantly associated with high cellular Ara-C and Dau resistance in univariate as well as multivariate analyses. FAB subtypes with highest and lowest cellular Ara-C resistance were M4 and M5, respectively (P < 0.01, one-way anova), whereas FAB subtypes with highest and lowest cellular Dau resistance were M4 and M1, respectively (P < 0.01, one-way anova). By contrast, no significant differences in cellular drug resistance towards Acla could be demonstrated among FAB subtypes. Furthermore, in two cohorts of AML patients treated by two different regimens for remission induction over a period of 15 yr (1985-94, n = 159 and 1995-99, n = 76, respectively) we demonstrate in univariate analyses a significance of CD14 expression with respect to clinical outcome. With the exception of significance to probability of obtaining complete remission in the first cohort (P = 0.03, logistic regression), this significance was, however, lost in multivariate analyses. It was demonstrated that FAB-M4 patients were older than M5 patients and that high CD14 expression was associated with the presence of secondary AML and older age. We conclude that although cases with high blast cell CD14 expression (and FAB-M4 cases) were more resistant to Ara-C as well as Dau in vitro, the clinical and biological significance of this may be debatable because of interactions with major prognostic factors in AML.

show abstract

Section: Methodsmentioning

confidence: 99%

FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara‐C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia

Nørgaard¹,

Olesen²,

Olesen³

et al. 2001

European J of Haematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Leukemic blasts express CD13 on the surface in between 66 and 82% of acute myeloid leukemias (AMLs) [12][13][14][15], and CD13 is therefore used as one of the routine markers in diagnosis of AML. Since neither function nor mechanisms regulating lineage-restricted expression of CD13 are fully elucidated for myeloid cells, we became interested in comparing AML cases being CD13 surface positive and negative, respectively, to gain further insight into how expression of CD13 is regulated in AML.…”

Section: Introductionmentioning

confidence: 99%

Identification of acute myeloid leukemia patients with diminished expression of CD13 myeloid transcripts by competitive reverse transcription polymerase chain reaction (RT-PCR)

Dybkær

Pedersen

et al. 2000

Leukemia Research

View full text Add to dashboard Cite

Normal myeloid cells of monocytic and granulocytic origin express the metallopeptidase cluster of differentiation 13 (CD13) on the surface just as leukemic blasts in most acute myeloid leukemias (AML). A minor percentage of AML patients, however, lack the surface expression of CD13 antigen. To study this difference in CD13 surface expression, specific CD13 mRNA from 44 individuals were quantified by competitive reverse transcription polymerase chain reaction (RT-PCR). Absolute values for CD13 transcripts were normalised against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript levels to control for variations in sample preparation and mRNA degradation. By correlating normalised CD13 transcript levels and CD13 surface expression, a subgroup of AML patients was identified, having simultaneous diminished levels of myeloid CD13 transcripts and surface expression of the corresponding antigen. For this subgroup we suggest CD13/aminopeptidase N (APN) gene expression to be restricted primarily by limited amounts of transcripts. For the majority of AML patients determinants in addition to transcript levels must be involved in regulating CD13/APN gene expression.

show abstract

Immunophenotyping and Cytogenetic/Molecular Genetic Analysis

2017

Leukaemia Diagnosis

View full text Add to dashboard Cite

First-line diagnosis based on immunological phenotyping in suspected acute leukemia: A prospective study

Cited by 17 publications

References 32 publications

FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara‐C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia

FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara‐C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia

Identification of acute myeloid leukemia patients with diminished expression of CD13 myeloid transcripts by competitive reverse transcription polymerase chain reaction (RT-PCR)

Immunophenotyping and Cytogenetic/Molecular Genetic Analysis

Contact Info

Product

Resources

About